CAR T-Cell Therapy Granted Priority Review for DLBCL – Cancer Network
|
CAR T-Cell Therapy Granted Priority Review for DLBCL
Cancer Network Other CAR T-cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B-cell precursor acute lymphoblastic leukemia and axicabtagene ciloleucil (aci-cel … |
